Lead Product(s) : SFA-002,Calcium,Magnesium
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
SFA Thera Announces Completion of Enrollment in Phase 1b Trial of SFA-002 for Psoriasis
Details : SFA002 is an oral drug for the treatment of mild-moderate psoriasis. It has a potential multi-target and disease-modifying therapeutic that has demonstrated efficacy, safety and durability.
Brand Name : SFA-002
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 30, 2024
Lead Product(s) : SFA-002,Calcium,Magnesium
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Vitamin D,Calcium,Potassium
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
BioAdaptives, Inc. Commences Development of a New Supplement for Womens Health
Details : PluriPain-PMS, an advanced, all natural anti-inflammatory and mood-enhancing Women’s Health formula to combat specific symptoms associated with the menstrual cycle.
Brand Name : PluriPain-PMS
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 05, 2023
Lead Product(s) : Vitamin D,Calcium,Potassium
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Glycine,Calcium
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Approved
Sponsor : Cipla
Deal Size : $48.6 million
Deal Type : Acquisition
Cipla to Acquire South Africa-based Actor Pharma
Details : Through the acquisition, Cipla strengthen its wellness portfolio by gaining access of Nozohaem (glycine and Calcium), a unique, gel treatment for nosebleeds that stops the bleeding in moments.
Brand Name : Nozohaem
Molecule Type : Small molecule
Upfront Cash : $48.6 million
September 05, 2023
Lead Product(s) : Glycine,Calcium
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Approved
Sponsor : Cipla
Deal Size : $48.6 million
Deal Type : Acquisition
Jazz Pharmaceuticals to Present New Data at SLEEP 2022 Reinforcing Leadership in Sleep Medicine
Details : Xywav (Calcium) is a lower-sodium oxybate approved by FDA for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy and for the treatment of idiopathic hypersomnia in adults.
Brand Name : Xywav
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 01, 2022
FDA Grants First of its Kind Indication for Chronic Sleep Disorder Treatment
Details : This FDA approval is based on the global Phase 3 double-blind, multicenter, placebo-controlled, randomized withdrawal study that demonstrated the efficacy and safety of Xywav for the treatment of idiopathic hypersomnia in adults.
Brand Name : Xywav
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 12, 2021
Jazz Pharmaceuticals Presents 18 Abstracts in Sleep Medicine at SLEEP 2021
Details : Results from the Phase 3, placebo-controlled, double-blind, randomized withdrawal study of Xywav in adults with idiopathic hypersomnia including an oral presentation of the correlation of the idiopathic hypersomnia severity scale score with other measure...
Brand Name : Xywav
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 09, 2021
Details : Xywav demonstrated highly statistically significant differences in median change in weekly number of cataplexy attacks and Epworth Sleepiness Scale scores compared to placebo.
Brand Name : Xywav
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 20, 2020
Details : All patients were treated with Xywav during the open-label titration period and clinically meaningful improvements in the Epworth Sleepiness Scale (ESS) were observed.
Brand Name : Xywav
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 08, 2020
LOOKING FOR A SUPPLIER?
Reset All
